Press Releases

Novartis Institutes for BioMedical Research Selects Feinstein Kean Healthcare as Agency of Record

Cambridge, MA, February 19, 2004 — Feinstein Kean Healthcare (FKH), a leading public relations firm specializing in pharmaceutical and biotechnology communications, has been named agency of record by the Novartis Institutes for BioMedical Research (NIBR), Novartis’ global research organization. Headquartered in Cambridge, Massachusetts, with research facilities around the world, NIBR’s mission is to develop innovative medicines reliably and predictably for patients worldwide.

“Feinstein Kean Healthcare’s experience and talent at the intersection of the biotechnology and pharmaceutical industries will be an important asset to NIBR as we continue to expand and evolve Novartis’ novel approach to drug discovery,” commented Fintan Steele, PhD, vice president and global head of communications for NIBR. “After an extensive search, it became clear that Feinstein Kean’s proven credentials in science-based communications and strategy are a natural fit for NIBR.”

Scientists at NIBR are blazing a new path in drug discovery by integrating various scientific disciplines, fostering interaction among scientists from within and outside of Novartis, and developing partnerships with academic research institutions and biotechnology companies to move beyond the traditional boundaries of translational research.

What sets FKH apart among communications firms is its role in and for the biotechnology industry. This focus, along with the fact that the firm is headquartered in the biotech hub of Cambridge, has allowed FKH to develop close ties to the industry, as well as long standing relationships with key members of the media and investment communities.

“We look forward to helping NIBR communicate the tremendous value of its new approach to scientific discovery and to partnerships,” said Marcia A. Kean, chief executive officer of Feinstein Kean Healthcare. “Looking ahead, NIBR’s scientific innovations will no doubt have a major impact on healthcare, and we are very proud to be working with them.”

###

About Feinstein Kean Healthcare
Feinstein Kean Healthcare (FKH), a wholly-owned subsidiary of Ogilvy Public Relations Worldwide, specializes in integrated corporate and product communications for the biotechnology and pharmaceutical industries. The firm’s clients include the full spectrum of therapeutic discovery, development, and technology platform companies as well as several of the world’s top 10 Big Pharma companies. For more information, visit www.fkhealth.com.

###

About Ogilvy Public Relations Worldwide
Ogilvy Public Relations Worldwide is a global marketing communications firm, with offices in more than 60 cities around the world. Entering its 24th year providing public relations solutions, Ogilvy Public Relations Worldwide has specialties in consumer marketing, corporate (B2B), health & medical, social marketing, technology, public affairs, government relations and entertainment. Through its subsidiary Feinstein Kean Healthcare, Ogilvy Public Relations Worldwide provides communication consulting to biotechnology companies. The Holmes Report has named Ogilvy Public Relations Worldwide 2003 International Agency of the Year; marking the fourth consecutive year the firm has been awarded “Agency of the Year.” Ogilvy Public Relations Worldwide is part of the WPP Group, the world’s largest marketing communications company (NASDAQ: WPPGY, www.wpp.com). For more information, visit our Web site at www.ogilvypr.com.